Gyre Therapeutics
GYRE
63 hedge funds and large institutions have $107M invested in Gyre Therapeutics in 2014 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 16 increasing their positions, 22 reducing their positions, and 18 closing their positions.
203% more call options, than puts
Call options by funds: $3.41M | Put options by funds: $1.12M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
2% less funds holding
Funds holding: 64 → 63 (-1)
9% less capital invested
Capital invested by funds: $117M → $107M (-$10.3M)
27% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 22
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
AllianceBernstein
Nashville,
Tennessee
| – | -$114K | -31 | Closed |
|
77
Prudential Financial
Newark,
New Jersey
| – | -$99K | -26 | Closed |
|
|
NI
78
Numeric Investors
Boston,
Massachusetts
| – | -$80K | -21 | Closed |
|
|
SIM
79
Spark Investment Management
New York
| – | -$69K | -19 | Closed |
|
|
OAM
80
Oxford Asset Management
Oxford,
United Kingdom
| – | -$54K | -14 | Closed |
|
81
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
| – | -$37K | -10 | Closed |
|
|
TRCT
82
Tower Research Capital (TRC)
New York
| – | -$13K | -3 | Closed |
|
|
CCMH
83
Cornerstone Capital Management Holdings
New York
| – | -$1K | – | – |
|
GYRE Hedge Fund Activity: Q2 2014 in Review
63 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q2 2014, worth a combined $107M — down 8.8% from $117M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of GYRE and 17 opened new positions — a net loss of 1 holder — while 22 trimmed existing stakes and 16 added.
The largest buyer was BVF Inc, adding an estimated $2M. The largest seller was Deerfield Management, exiting entirely with an estimated $2.93M sold.
- 63 institutional investors held Gyre Therapeutics (GYRE) as of Q2 2014, down from 64 in Q1 2014.
- Funds reported $107M of Gyre Therapeutics stock for Q2 2014, down 8.8% quarter-over-quarter.
- 17 funds opened new Gyre Therapeutics positions in Q2 2014 and 18 closed out, a net change of -1 holder.
- The largest Gyre Therapeutics buyer in Q2 2014 was BVF Inc, an estimated $2M added.
- The largest Gyre Therapeutics seller in Q2 2014 was Deerfield Management, an estimated $2.93M sold.
Based on aggregated 13F filings for Q2 2014.